tiprankstipranks
Trending News
More News >
XBiotech (XBIT)
NASDAQ:XBIT

XBiotech (XBIT) Price & Analysis

Compare
341 Followers

XBIT Stock Chart & Stats

$2.53
-$0.18(-4.23%)
At close: 4:00 PM EST
$2.53
-$0.18(-4.23%)

XBiotech News

XBIT FAQ

What was XBiotech’s price range in the past 12 months?
XBiotech lowest stock price was $2.09 and its highest was $7.24 in the past 12 months.
    What is XBiotech’s market cap?
    XBiotech’s market cap is $73.17M.
      When is XBiotech’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were XBiotech’s earnings last quarter?
      Currently, no data Available
      Is XBiotech overvalued?
      According to Wall Street analysts XBiotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does XBiotech pay dividends?
        XBiotech pays a Notavailable dividend of $2.47 which represents an annual dividend yield of N/A. See more information on XBiotech dividends here
          What is XBiotech’s EPS estimate?
          XBiotech’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does XBiotech have?
          XBiotech has 30,487,732 shares outstanding.
            What happened to XBiotech’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of XBiotech?
            Currently, no hedge funds are holding shares in XBIT
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              XBiotech Stock Smart Score

              Company Description

              XBiotech

              XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
              Similar Stocks
              Company
              Price & Change
              Follow
              Alterity Therapeutics
              Immunic
              Nautilus Biotechnolgy
              Acumen Pharmaceuticals
              Invivyd

              Ownership Overview

              12.54%4.05%1.04%80.73%
              12.54%
              Insiders
              1.04% Other Institutional Investors
              80.73% Public Companies and
              Individual Investors

              Options Prices

              Currently, No data available
              ---
              Popular Stocks